Jordan J Feld1, Norah A Terrault2, Hsing-Hua S Lin3, Steven H Belle3, Raymond T Chung4, Naoky Tsai5, Mandana Khalili2, Robert Perrillo6, Stewart L Cooper7, Marc G Ghany8, Harry L A Janssen1, Anna S Lok9. 1. Toronto Centre for Liver Disease, University of Toronto, Toronto, Canada. 2. University of California San Francisco, San Francisco, CA. 3. Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA. 4. Massachusetts General Hospital, Harvard University, Boston, MA. 5. University of Hawaii, Honolulu, HI. 6. Baylor University Medical Center, Baylor University, Dallas, TX. 7. San Francisco Center for Liver Disease, California Pacific Medical Center, San Francisco, CA. 8. Liver Diseases Branch, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD. 9. University of Michigan, Ann Arbor, MI.
Abstract
Monotherapy with interferon or nucleoside analog is generally not recommended during the immune-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase. Small pediatric studies reported efficacy with combination nucleoside analog and interferon therapy. The aim of this study was to evaluate the safety and efficacy of the combination of entecavir and peginterferon in adults in the IT phase of chronic HBV infection. Hepatitis B e antigen (HBeAg)-positive adults with HBV DNA > 107 IU/mL and alanine aminotransferase (ALT) ≤ 1.5 times the upper limit of normal (ULN) (male: ≤ 45, female: ≤ 30 U/L) received entecavir 0.5 mg daily for 8 weeks followed by the addition of peginterferon alfa-2a 180 µg/week to entecavir for an additional 40 weeks. The primary endpoint was HBeAg loss and HBV DNA ≤ 1,000 IU/mL 48 weeks after end of treatment (EOT). Among 28 participants from 11 sites, the median age was 37.2 (range: 22-61) years, 54% were male, and 96% were Asian. Nearly all were infected with genotype C (64%) or B (32%). Median baseline HBV DNA was 8.2 log10 IU/mL, and ALT was 0.9 times the ULN. Although one (4%) participant cleared HBeAg, none met the primary endpoint of both HBeAg loss AND HBV DNA ≤ 1,000 IU/mL 48 weeks post-EOT. ALT elevations > 5 times the ULN occurred in eight (29%) participants, and none were associated with icterus. Forty-eight weeks posttreatment, HBV DNA rebounded to baseline levels in all participants, including the participant who lost HBeAg, and ALT values returned to near baseline levels in all but four participants. Conclusion: A lead-in strategy of 8 weeks of entecavir followed by combination peginterferon and entecavir therapy for 40 weeks had limited efficacy in adults in the IT phase of chronic HBV infection and cannot be recommended.
Monotherapy with interferon or nucleoside analog is generally not recommended during the immune-tolerant (IT) phase of chronic hepatitis B virus (HBV) infection. Recognition that high HBV DNA levels are associated with hepatocellular carcinoma has increased interest in treating HBV in the IT phase. Small pediatric studies reported efficacy with combination nucleoside analog and interferon therapy. The aim of this study was to evaluate the safety and efficacy of the combination of entecavir and peginterferon in adults in the IT phase of chronic HBV infection. Hepatitis B e antigen (HBeAg)-positive adults with HBV DNA > 107 IU/mL and alanine aminotransferase (ALT) ≤ 1.5 times the upper limit of normal (ULN) (male: ≤ 45, female: ≤ 30 U/L) received entecavir 0.5 mg daily for 8 weeks followed by the addition of peginterferon alfa-2a 180 µg/week to entecavir for an additional 40 weeks. The primary endpoint was HBeAg loss and HBV DNA ≤ 1,000 IU/mL 48 weeks after end of treatment (EOT). Among 28 participants from 11 sites, the median age was 37.2 (range: 22-61) years, 54% were male, and 96% were Asian. Nearly all were infected with genotype C (64%) or B (32%). Median baseline HBV DNA was 8.2 log10 IU/mL, and ALT was 0.9 times the ULN. Although one (4%) participant cleared HBeAg, none met the primary endpoint of both HBeAg loss AND HBV DNA ≤ 1,000 IU/mL 48 weeks post-EOT. ALT elevations > 5 times the ULN occurred in eight (29%) participants, and none were associated with icterus. Forty-eight weeks posttreatment, HBV DNA rebounded to baseline levels in all participants, including the participant who lost HBeAg, and ALT values returned to near baseline levels in all but four participants. Conclusion: A lead-in strategy of 8 weeks of entecavir followed by combination peginterferon and entecavir therapy for 40 weeks had limited efficacy in adults in the IT phase of chronic HBV infection and cannot be recommended.
Authors: Eric T T L Tjwa; Gertine W van Oord; Joost P Hegmans; Harry L A Janssen; Andrea M Woltman Journal: J Hepatol Date: 2010-09-06 Impact factor: 25.083
Authors: Jurriën G P Reijnders; Vincent Rijckborst; Milan J Sonneveld; Sandra M J Scherbeijn; Charles A B Boucher; Bettina E Hansen; Harry L A Janssen Journal: J Hepatol Date: 2010-11-05 Impact factor: 25.083
Authors: Patrick T F Kennedy; Elena Sandalova; Juandy Jo; Upkar Gill; Ines Ushiro-Lumb; Anthony T Tan; Sandhia Naik; Graham R Foster; Antonio Bertoletti Journal: Gastroenterology Date: 2012-06-15 Impact factor: 22.682
Authors: George K K Lau; Teerha Piratvisuth; Kang Xian Luo; Patrick Marcellin; Satawat Thongsawat; Graham Cooksley; Edward Gane; Michael W Fried; Wan Cheng Chow; Seung Woon Paik; Wen Yu Chang; Thomas Berg; Robert Flisiak; Philip McCloud; Nigel Pluck Journal: N Engl J Med Date: 2005-06-30 Impact factor: 91.245
Authors: Panagiota Maravelia; Lars Frelin; Yi Ni; Noelia Caro Pérez; Gustaf Ahlén; Neetu Jagya; Georg Verch; Lieven Verhoye; Lena Pater; Magnus Johansson; Anna Pasetto; Philip Meuleman; Stephan Urban; Matti Sällberg Journal: J Infect Dis Date: 2021-01-04 Impact factor: 5.226
Authors: Anna S Lok; Robert Perrillo; Christina M Lalama; Michael W Fried; Steven H Belle; Marc G Ghany; Mandana Khalili; Robert J Fontana; Richard K Sterling; Norah Terrault; Jordan J Feld; Adrian M Di Bisceglie; Daryl T Y Lau; Mohamed Hassan; Harry L A Janssen Journal: Hepatology Date: 2021-05-21 Impact factor: 17.425